{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:13:07Z","timestamp":1792800787556,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific research project of Shaanxi Administration of Traditional Chinese Medicine","award":["SZY-KJCYC-2025-ZY-013"],"award-info":[{"award-number":["SZY-KJCYC-2025-ZY-013"]}],"id":[{"id":"https:\/\/ror.org\/027hagy81","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073775"],"award-info":[{"award-number":["82073775"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Laboratory of New Drug Delivery System and New Technology for Formulation, Shaanxi Administration of Traditional Chinese Medicine","award":["2023-ZDYJSY-001"],"award-info":[{"award-number":["2023-ZDYJSY-001"]}],"id":[{"id":"https:\/\/ror.org\/027hagy81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Project from Air Force Medical University","award":["20023JSYX16"],"award-info":[{"award-number":["20023JSYX16"]}],"id":[{"id":"https:\/\/ror.org\/00ms48f15","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02496-3","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:34:36Z","timestamp":1763019276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The enhanced cancer nanovaccine by bidirectionally blocking CXCL12\/CXCR4 axis to inhibit the recurrence and metastasis of triple-negative breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Miao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangle","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daozhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"45","key":"2496_CR1","doi-asserted-by":"publisher","first-page":"30943","DOI":"10.1021\/acsnano.3c12967","volume":"18","author":"Z Peng","year":"2024","unstructured":"Peng Z, Zhao T, Gao P, et al. Tumor-derived extracellular vesicles enable tumor tropism chemo-genetherapy for local immune activation in triple-negative breast cancer. ACS Nano. 2024;18(45):30943\u201356.","journal-title":"ACS Nano"},{"issue":"3","key":"2496_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35(3):428\u201340.","journal-title":"Cancer Cell"},{"key":"2496_CR3","first-page":"440","volume":"31","author":"P Sharma","year":"2024","unstructured":"Sharma P, Otto M. Multifunctional nanocomposites modulating the tumor microenvironment for enhanced cancer immunotherapy. Bioact Mater. 2024;31:440\u201362.","journal-title":"Bioact Mater"},{"key":"2496_CR4","doi-asserted-by":"publisher","first-page":"115514","DOI":"10.1016\/j.biopha.2023.115514","volume":"167","author":"M Chen","year":"2023","unstructured":"Chen M, Bie L, Ying J. Cancer cell-intrinsic PD-1: its role in malignant progression and immunotherapy. Biomed Pharmacother. 2023;167:115514.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2496_CR5","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and ctla-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425\u201334.","journal-title":"Nat Immunol"},{"issue":"22","key":"2496_CR6","doi-asserted-by":"publisher","first-page":"e2212267","DOI":"10.1002\/adma.202212267","volume":"35","author":"B Guo","year":"2023","unstructured":"Guo B, Yang F, Zhang L, et al. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with alphapd-l1 for enhanced cancer immunotherapy. Adv Mater. 2023;35(22):e2212267.","journal-title":"Adv Mater"},{"issue":"6","key":"2496_CR7","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/cncr.34084","volume":"128","author":"RR Malla","year":"2022","unstructured":"Malla RR, Vasudevaraju P, Vempati RK, et al. Regulatory t cells: their role in triple-negative breast cancer progression and metastasis. Cancer. 2022;128(6):1171\u201383.","journal-title":"Cancer"},{"issue":"1","key":"2496_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22(1):145.","journal-title":"Mol Cancer"},{"issue":"5","key":"2496_CR9","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1039\/D3MH00092C","volume":"10","author":"Z Yu","year":"2023","unstructured":"Yu Z, Wang D, Qi Y, et al. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy. Mater Horiz. 2023;10(5):1661\u201377.","journal-title":"Mater Horiz"},{"issue":"33","key":"2496_CR10","doi-asserted-by":"publisher","first-page":"e2403158","DOI":"10.1002\/advs.202403158","volume":"11","author":"X An","year":"2024","unstructured":"An X, Chen Z, Luo Y, et al. Light-activated in situ vaccine with enhanced cytotoxic t lymphocyte infiltration and function for potent cancer immunotherapy. Adv Sci (Weinh). 2024;11(33):e2403158.","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"2496_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41573-024-00974-9","volume":"23","author":"N Gong","year":"2024","unstructured":"Gong N, Alameh M, El-Mayta R, et al. Enhancing in situ cancer vaccines using delivery technologies. Nat Rev Drug Discov. 2024;23(8):607\u201325.","journal-title":"Nat Rev Drug Discov"},{"key":"2496_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nantod.2022.101621","volume":"46","author":"R Li","year":"2022","unstructured":"Li R, Chen Z, Li J, et al. Nano-drug delivery systems for t cell-based immunotherapy. Nano Today. 2022;46:16.","journal-title":"Nano Today"},{"key":"2496_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.imlet.2019.11.007","volume":"217","author":"A Mousavi","year":"2020","unstructured":"Mousavi A. CXCL12\/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett. 2020;217:91\u2013115.","journal-title":"Immunol Lett"},{"issue":"1","key":"2496_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1021\/acsnano.9b03978","volume":"14","author":"Y Xie","year":"2020","unstructured":"Xie Y, Hang Y, Wang Y, et al. Stromal modulation and treatment of metastatic pancreatic cancer with local intraperitoneal triple mirna\/sirna nanotherapy. ACS Nano. 2020;14(1):255\u201371.","journal-title":"ACS Nano"},{"issue":"6","key":"2496_CR15","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","volume":"16","author":"MS Alghamri","year":"2022","unstructured":"Alghamri MS, Banerjee K, Mujeeb AA, et al. Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy. ACS Nano. 2022;16(6):8729\u201350.","journal-title":"ACS Nano"},{"issue":"19\u201320","key":"2496_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19\u201320):1267\u201384.","journal-title":"Genes Dev"},{"issue":"4","key":"2496_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41568-023-00549-7","volume":"23","author":"M Tsoumakidou","year":"2023","unstructured":"Tsoumakidou M. The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 2023;23(4):258\u201369.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2496_CR18","doi-asserted-by":"publisher","first-page":"9830","DOI":"10.1021\/acsnano.8b00967","volume":"12","author":"L Shen","year":"2018","unstructured":"Shen L, Li J, Liu Q, et al. Local Blockade of Interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers. ACS Nano. 2018;12(10):9830\u201341.","journal-title":"ACS Nano"},{"key":"2496_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jconrel.2021.12.026","volume":"341","author":"J Dong","year":"2022","unstructured":"Dong J, Zhu C, Zhang F, et al. Attractive\/adhesion force dual-regulatory nanogels capable of cxcr4 antagonism and autophagy Inhibition for the treatment of metastatic breast cancer. J Control Release. 2022;341:892\u2013903.","journal-title":"J Control Release"},{"issue":"19","key":"2496_CR20","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1158\/1078-0432.CCR-14-0914","volume":"21","author":"S Scala","year":"2015","unstructured":"Scala S. Molecular pathways: targeting the CXCR4-CXCL12 axis\u2013untapped potential in the tumor microenvironment. Clin Cancer Res. 2015;21(19):4278\u201385.","journal-title":"Clin Cancer Res"},{"key":"2496_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jconrel.2021.04.029","volume":"334","author":"M Zhou","year":"2021","unstructured":"Zhou M, Luo C, Zhou Z, et al. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced Immunogenic cell death and CXCR4 Blockade. J Control Release. 2021;334:248\u201362.","journal-title":"J Control Release"},{"issue":"17","key":"2496_CR22","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","volume":"26","author":"W Zhou","year":"2019","unstructured":"Zhou W, Guo S, Liu M, et al. Targeting CXCL12\/CXCR4 axis in tumor immunotherapy. Curr Med Chem. 2019;26(17):3026\u201341.","journal-title":"Curr Med Chem"},{"issue":"7","key":"2496_CR23","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.apsb.2022.12.012","volume":"13","author":"J Dong","year":"2023","unstructured":"Dong J, Zhu C, Huang Y, et al. Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator. Acta Pharm Sin B. 2023;13(7):3106\u201320.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"2496_CR24","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1038\/s41467-024-47111-z","volume":"15","author":"M Zhou","year":"2024","unstructured":"Zhou M, Liu C, Li B, et al. Cell surface patching via CXCR4-targeted nanothreads for cancer metastasis Inhibition. Nat Commun. 2024;15(1):2763.","journal-title":"Nat Commun"},{"key":"2496_CR25","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.actbio.2023.05.030","volume":"166","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang B, Wang H, et al. Reversibly double locked hydroxycamptothecin prodrug nanoparticles for targeted chemotherapy of lung cancer. Acta Biomater. 2023;166:593\u2013603.","journal-title":"Acta Biomater"},{"issue":"19","key":"2496_CR26","doi-asserted-by":"publisher","first-page":"12194","DOI":"10.1021\/acsnano.4c00413","volume":"18","author":"L Lei","year":"2024","unstructured":"Lei L, Yan J, Xin K, et al. Engineered bacteriophage-based in situ vaccine remodels a tumor microenvironment and elicits potent antitumor immunity. ACS Nano. 2024;18(19):12194\u2013209.","journal-title":"ACS Nano"},{"key":"2496_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.jconrel.2020.12.042","volume":"330","author":"S Zeng","year":"2021","unstructured":"Zeng S, Ou H, Gao Z, et al. Hcpt-peptide prodrug with tumor microenvironment -responsive morphology transformable characteristic for boosted bladder tumor chemotherapy. J Control Release. 2021;330:715\u201325.","journal-title":"J Control Release"},{"key":"2496_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jconrel.2023.05.002","volume":"358","author":"Q Chen","year":"2023","unstructured":"Chen Q, Huang J, Ye Y, et al. Delivery of hydroxycamptothecin via sonoporation: an effective therapy for liver fibrosis. J Control Release. 2023;358:319\u201332.","journal-title":"J Control Release"},{"issue":"5","key":"2496_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265\u201380.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2496_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-022-01298-z","volume":"8","author":"Z Lu","year":"2023","unstructured":"Lu Z, Shen J, Yang J, et al. Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduct Target Ther. 2023;8(1):39.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2496_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, et al. Therapeutic sirna: state of the Art. Signal Transduct Target Ther. 2020;5(1):101.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2496_CR32","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","volume":"23","author":"Q Tang","year":"2024","unstructured":"Tang Q, Khvorova A. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discov. 2024;23(5):341\u201364.","journal-title":"Nat Rev Drug Discov"},{"key":"2496_CR33","doi-asserted-by":"publisher","first-page":"1568865","DOI":"10.3389\/fmolb.2025.1568865","volume":"12","author":"MR Brogna","year":"2025","unstructured":"Brogna MR, Varone V, Delsesto M, et al. The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge. Front Mol Biosci. 2025;12:1568865.","journal-title":"Front Mol Biosci"},{"issue":"5","key":"2496_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers12051307","volume":"12","author":"A Sebastian","year":"2020","unstructured":"Sebastian A, Hum NR, Martin KA, et al. Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer. Cancers (Basel). 2020;12(5):22.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2496_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41419-025-07588-y","volume":"16","author":"E Sun","year":"2025","unstructured":"Sun E, Choi J, Park M, et al. Fgfr4 promotes Caf activation through the cxcl10-cxcr3 axis in colon cancer. Cell Death Dis. 2025;16(1):424.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2496_CR36","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-024-55658-0","volume":"16","author":"J Zou","year":"2025","unstructured":"Zou J, Jiang C, Hu Q, et al. Tumor microenvironment-responsive engineered hybrid nanomedicine for photodynamic-immunotherapy via multi-pronged amplification of reactive oxygen species. Nat Commun. 2025;16(1):424.","journal-title":"Nat Commun"},{"issue":"6","key":"2496_CR37","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.1021\/acsnano.3c09608","volume":"18","author":"Y Chao","year":"2024","unstructured":"Chao Y, Lee Y, Tseng C, et al. Improved cap nanoparticles for nucleic acid and protein delivery to neural primary cultures and stem cells. ACS Nano. 2024;18(6):4822\u201339.","journal-title":"ACS Nano"},{"key":"2496_CR38","doi-asserted-by":"publisher","first-page":"153437","DOI":"10.1016\/j.phymed.2020.153437","volume":"81","author":"H Wu","year":"2021","unstructured":"Wu H, Lin J, Liu Y, et al. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT\/MTOR signaling pathway. Phytomedicine. 2021;81:153437.","journal-title":"Phytomedicine"},{"key":"2496_CR39","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.2147\/IJN.S457782","volume":"19","author":"J Peng","year":"2024","unstructured":"Peng J, Li S, Ti H. Sensitize tumor immunotherapy: Immunogenic cell death inducing nanosystems. Int J Nanomed. 2024;19:5895\u2013930.","journal-title":"Int J Nanomed"},{"issue":"1","key":"2496_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12967-023-04017-6","volume":"21","author":"L Galluzzi","year":"2023","unstructured":"Galluzzi L, Kepp O, Hett E, et al. Immunogenic cell death in cancer: concept and therapeutic implications. J Transl Med. 2023;21(1):162.","journal-title":"J Transl Med"},{"key":"2496_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jconrel.2023.08.002","volume":"361","author":"X Jiang","year":"2023","unstructured":"Jiang X, Wu L, Zhang M, et al. Biomembrane nanostructures: multifunctional platform to enhance tumor chemoimmunotherapy via effective drug delivery. J Control Release. 2023;361:510\u201333.","journal-title":"J Control Release"},{"issue":"1","key":"2496_CR42","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/imr.13261","volume":"321","author":"J Huang","year":"2024","unstructured":"Huang J, Duan F, Xie C, et al. Microbes mediated Immunogenic cell death in cancer immunotherapy. Immunol Rev. 2024;321(1):128\u201342.","journal-title":"Immunol Rev"},{"issue":"49","key":"2496_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/adfm.202307013","volume":"33","author":"M Shen","year":"2023","unstructured":"Shen M, Wang Y, Bing T, et al. Alendronate triggered dual-cascade targeting prodrug nanoparticles for enhanced tumor penetration and Sting activation of osteosarcoma. Adv Funct Mater. 2023;33(49):15.","journal-title":"Adv Funct Mater"},{"issue":"2","key":"2496_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99\u2013115.","journal-title":"Nat Rev Drug Discov"},{"key":"2496_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2021.03.028","volume":"333","author":"Y Hang","year":"2021","unstructured":"Hang Y, Tang S, Tang W, et al. Polycation fluorination improves intraperitoneal Sirna delivery in metastatic pancreatic cancer. J Control Release. 2021;333:139\u201350.","journal-title":"J Control Release"},{"key":"2496_CR46","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","volume":"11","author":"Y Shi","year":"2020","unstructured":"Shi Y, Riese DJN, Shen J. The role of the cxcl12\/cxcr4\/cxcr7 chemokine axis in cancer. Front Pharmacol. 2020;11:574667.","journal-title":"Front Pharmacol"},{"issue":"11","key":"2496_CR47","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, et al. CXCL12-CXCR4\/CXR7 axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19(11):3341\u201359.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2496_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12951-025-03476-x","volume":"23","author":"S Zhang","year":"2025","unstructured":"Zhang S, Jiang H, Zhao C, et al. CXCL12-targeting Sirna nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma. J Nanobiotechnol. 2025;23(1):519.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"2496_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41419-024-07270-9","volume":"16","author":"H Bai","year":"2025","unstructured":"Bai H, Zhu X, Gao L, et al. Erg mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFR\u03b1+ cancer-associated fibroblasts during hepatocarcinogenesis. Cell Death Dis. 2025;16(1):26.","journal-title":"Cell Death Dis"},{"key":"2496_CR50","doi-asserted-by":"crossref","unstructured":"Corrado M, Pearce EL. Targeting memory t cell metabolism to improve immunity. J Clin Invest. 2022;132(1):e148546.","DOI":"10.1172\/JCI148546"},{"issue":"1","key":"2496_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, et al. T cells in health and disease. Signal Transduct Target Ther. 2023;8(1):235.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2496_CR52","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","volume":"30","author":"Y Liu","year":"2016","unstructured":"Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016;30(5):668\u201381.","journal-title":"Cancer Cell"},{"issue":"1","key":"2496_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2496_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/1541-7786.MCR-20-0115","volume":"19","author":"E Kawakita","year":"2021","unstructured":"Kawakita E, Yang F, Kumagai A, et al. Metformin mitigates DPP-4 inhibitor-induced breast cancer metastasis via suppression of Mtor signaling. Mol Cancer Res. 2021;19(1):61\u201373.","journal-title":"Mol Cancer Res"},{"issue":"32","key":"2496_CR55","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1038\/s41388-018-0263-7","volume":"37","author":"DK Ahirwar","year":"2018","unstructured":"Ahirwar DK, Nasser MW, Ouseph MM, et al. Fibroblast-derived cxcl12 promotes breast cancer metastasis by facilitating tumor cell intravasation. Oncogene. 2018;37(32):4428\u201342.","journal-title":"Oncogene"},{"issue":"1","key":"2496_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41568-018-0081-9","volume":"19","author":"NK Altorki","year":"2019","unstructured":"Altorki NK, Markowitz GJ, Gao D, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19(1):9\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2496_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2496_CR58","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ccell.2024.05.004","volume":"42","author":"CS Mcginnis","year":"2024","unstructured":"Mcginnis CS, Miao Z, Superville D, et al. The Temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024;42(6):1018\u201331.","journal-title":"Cancer Cell"},{"issue":"6","key":"2496_CR59","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1021\/acsnano.2c08834","volume":"17","author":"X Xu","year":"2023","unstructured":"Xu X, Wang Q, Qian X, et al. Spatial-drug-laden protease-activatable M1 macrophage system targets lung metastasis and potentiates antitumor immunity. ACS Nano. 2023;17(6):5354\u201372.","journal-title":"ACS Nano"},{"issue":"7868","key":"2496_CR60","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes M, Dalla E, Leader AM, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early Nsclc cells. Nature. 2021;595(7868):578\u201384.","journal-title":"Nature"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02496-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02496-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:03:11Z","timestamp":1763024591000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02496-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2496"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02496-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Air Force Medical University Institutional Animal Care and Utilization Committee (No: IACUC-20210820).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"290"}}